Orchid Pharma has allotted over 4.45 crore equity shares as part of its amalgamation with Dhanuka Laboratories. The company's paid-up capital now stands at ₹59.89 crore. The new shares are proposed for listing on BSE and NSE.
Orchid Pharma Completes Share Allotment Post Dhanuka Labs Amalgamation
4,45,86,052 equity shares allotted.
Paid-up capital now ₹59.89 crore.
Reader Takeaway: Successful amalgamation execution; focus shifts to share listing and integration.
What just happened
Orchid Pharma Limited has completed a significant step in its amalgamation with Dhanuka Laboratories Limited by allotting 4,45,86,052 fully paid-up equity shares. This corporate action follows the record date of July 23, 2026, and is part of the Scheme of Amalgamation that became effective on July 10, 2026.
Why this matters
This allotment formalizes the share issuance component of the amalgamation, consolidating the entities. It increases the company's paid-up share capital to ₹59.89 crore, represented by 5,98,85,200 shares. The successful completion of this step is crucial for the overall integration of Dhanuka Laboratories into Orchid Pharma and signals progress in the restructuring strategy.
The backstory
The amalgamation process has been underway, with the Scheme of Amalgamation receiving necessary approvals. The record date for determining eligible shareholders for the new equity shares was July 23, 2026, and the amalgamation became effective on July 10, 2026.
What changes now
The immediate change is the increase in Orchid Pharma's issued and paid-up share capital. The key upcoming event will be the listing and trading of these newly allotted 4,45,86,052 equity shares on both the BSE and the National Stock Exchange of India. These new shares will rank equally with existing shares.
Risks to watch
Post-amalgamation integration challenges and the smooth listing of new shares on the exchanges are key factors to monitor. Any delays or unforeseen issues in the listing process could impact investor sentiment.
Peer comparison
While specific peer financial data is not provided in this filing, the amalgamation aims to create a larger entity. Performance will be benchmarked against other mid-cap pharmaceutical companies in India post-integration.
Context metrics (time-bound)
- Record Date: July 23, 2026
- Amalgamation Effective Date: July 10, 2026
- Shares Allotted: 4,45,86,052 equity shares
- Face Value: ₹10 per share
- Post-Allotment Paid-up Capital: ₹59.89 crore
- Post-Allotment Total Shares: 5,98,85,200
What to track next
Investors should keenly watch for official announcements regarding the exact date for the listing and commencement of trading for the newly allotted equity shares on the BSE and NSE.